Aclaris Therapeutics (ACRS) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 4, 2026, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and annual report before voting.

Voting matters and shareholder proposals

• Election of two directors: Anand Mehra, M.D. and Maxine Gowen, Ph.D.

• Advisory vote to approve compensation of named executive officers.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.

• Other business may be addressed as appropriate during the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director nominees and auditor ratification.